Curis Inc CRIS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $0.43
- Day Range
- $0.42–0.43
- 52-Week Range
- $0.41–2.94
- Bid/Ask
- $0.42 / $0.43
- Shares Outstanding
- 38.98M
- Market Cap
- $16.48M
- Volume/Avg
- 18,880 / 425,752
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.01
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 24
- Website
- https://www.curis.com
Valuation
|
Metric
|
CRIS
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.41 |
Price/Sales | 1.01 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CRIS
|
|---|---|
Quick Ratio | 1.00 |
Current Ratio | 1.11 |
Interest Coverage | −10.23 |
Quick Ratio
CRIS
Profitability
|
Metric
|
CRIS
|
|---|---|
Return on Assets (Normalized) | −154.01% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
CRIS
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Jmcgmhhdb | Bzkjxc | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Fwbgdwjn | Bhspwk | $64B | |||
| argenx SE ADR
ARGX
| Vzldknjr | Dch | $56B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Rgypzyq | Gzbzf | $39B | |||
| Royalty Pharma PLC Class A
RPRX
| Bydhvvzbs | Yvdvjs | $24B | |||
| BioNTech SE ADR
BNTX
| Fcmyjnpm | Bwtkn | $23B | |||
| Incyte Corp
INCY
| Ygpjqwnn | Jzvl | $22B | |||
| Moderna Inc
MRNA
| Yvzwqqvsz | Dtqn | $20B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Rztqfbbd | Wkyv | $15B | |||
| BridgeBio Pharma Inc
BBIO
| Vlndjwk | Kjrv | $13B |
United States